| Literature DB >> 22253993 |
Julie Y Culbertson1, Richard B Kreider, Mike Greenwood, Matthew Cooke.
Abstract
Muscle carnosine has been reported to serve as a physiological buffer, possess antioxidant properties, influence enzyme regulation, and affect sarcoplasmic reticulum calcium regulation. Beta-alanine (β-ALA) is a non-essential amino acid. β-ALA supplementation (e.g., 2-6 grams/day) has been shown to increase carnosine concentrations in skeletal muscle by 20-80%. Several studies have reported that β-ALA supplementation can increase high-intensity intermittent exercise performance and/or training adaptations. Although the specific mechanism remains to be determined, the ergogenicity of β-ALA has been most commonly attributed to an increased muscle buffering capacity. More recently, researchers have investigated the effects of co-ingesting β-ALA with creatine monohydrate to determine whether there may be synergistic and/or additive benefits. This paper overviews the theoretical rationale and potential ergogenic value of β-ALA supplementation with or without creatine as well as provides future research recommendations.Entities:
Keywords: anaerobic capacity; creatine monohydrate; ergogenic aids; muscular fatigue
Mesh:
Substances:
Year: 2010 PMID: 22253993 PMCID: PMC3257613 DOI: 10.3390/nu2010075
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Chemical structure of carnosine.
Summary of the effects of β-ALA supplementation on muscle carnosine concentrations.
| Authors | Population | Supplementation Protocol | Muscle Carnosine Concentration Effects | Performance Results |
|---|---|---|---|---|
| Baguet | 20 physically active males | 5-6 weeks of β-ALA or placebo (maltodextrin) | In soleus, carnosine increased 30% (p=0.003) with β-ALA and remained stable with placebo (p=0.867) | None measured |
| 2.4 g/day - first 2 days | In tibialis anterior, carnosine increased 27% (p=0.005) with β-ALA and decreased 17% (p=0.05) with placebo | |||
| 3.6 g/day - days 3-4 | In gastrocnemius, carnosine increased 23% (p=0.038) and did not change with placebo (p=0.740). | |||
| 4.8 g/day to end of study | Carnosine elimination was measured at 3 and 9 weeks after supplementation period | |||
| At 3 weeks, only 26.1% (in the soleus), 20.1% (in tibialis anterior) and 44.7% (in the gastrocnemius) of the increase had disappeared. There was no difference between β-ALA and placebo at this point (p=0.431) | ||||
| At 9 weeks, carnosine levels in all 3 muscles returned to initial values | ||||
| Harris | Study 3:21 physically active males Ages 26.1 ± 5.6 yrs | 4 weeks, 4 groups (I - IV): I) 800mg β-ALA x 4 daily (avg. 3.2g daily and 89.6g 4wk total)II) 8 daily doses of either 400 or 800mg β-ALA (avg. 6.4g daily and 145.6g 4wk total)III) 8 daily doses of 1000 or 2000 mg L-carnosine (364g 4wk total L-carnosine, corresponding to 143.3g β-ALA) IV) Placebo of maltodextrin at doses to match groups II and III | Increase in carnosine concentration greatest with carnosine supplementation, followed by group II, then group II β-ALA protocols. | None measured |
| Mean increase over 4 weeks (mmol·kg-1dm) | ||||
| I) 7.80 ± .36 (p < .05) | ||||
| II) 11.04 ± 2.68 (p < .05) | ||||
| III) 16.37 ± 3.03 (p < .05) | ||||
| IV) 1.87 ± 1.73 (p>.05) | ||||
| Derave | 15 male track athletes (sprinters) 18-24 yrs | 4-5 weeks β-ALA or placebo (maltodextrin) | No difference between groups for 400m running performance | |
| 2.4g/day - first 4 days | ↑ 47% with β-ALA | |||
| 3.6g/day - days 5-8 | No change with placebo | |||
| 4.8g/day to end of study | ||||
| ↑ 37% with β-ALA | ||||
| No change with placebo | ||||
| Hill | 25 physically active males | 10 weeks β-ALA: | β-ALA group, ↑ from 19.0 to 30.1 mmol/kg (58.8%) at 4 weeks and up to 34.7 mmol/kg (80.1%) at 10 weeks | No effect on body mass |
| 4g/day - wk 1 | Not significant between weeks 4 and 10 | ↑cycling capacity time at 110% with β-ALA | ||
| 4.8g/day - wk 2 | ||||
| 5.6g/day - wk 3 | ||||
| 6.4g/day - wk 4-10 |
Summary of recent β-ALA supplementation and exercise performance studies.
| Authors | Population | Supplementation Protocol | Exercise Testing Protocol | Performance Results |
|---|---|---|---|---|
| Baguet | 14 physically active males | 4 weeks of β-ALA or placebo (maltodextrin) | Maximal ramp exercise test on cycle ergometer to determine VO2peak, VT and gas exchange threshold | Exercise-induced acidosis was 19% lower with β-ALA |
| 2.4 g/day - first 2 days | Pre and Post supplementation: 3 x 6min cycle exercise bouts at 50% ∆ power output | No difference in VO2 throughout exercise before or after supplementation in either group | ||
| 3.6 g/day - days 3-4 | Time delay in the fast component was significantly shorter with β-ALA than placebo | |||
| 4.8 g/day to end of study | Does not support a role for acidosis in O2 deficit or the slow component of VO2 kinetics | |||
| Stout | 51 males | 4 groups: | PWCMFT test with EMG measurements on a cycle ergometer | β-ALA may delay the onset of neuromuscular fatigue, but no additive effects of creatine |
| Placebo - 34 g dextrose | Significant increase in PWCFT with β-ALA (14.5%) and creatine plus β-ALA (11%) compared to placebo | |||
| Creatine - 5.25 g creatine monohydrate and 34 g dextrose | ||||
| β-ALA - 1.6 g β-ALA plus 34 g dextrose | ||||
| β-ALA+Creatine - 5.35 g creatine monohydrate, 1.6 g β-ALA and 34 g dextrose | ||||
| 28 days of supplementation: | ||||
| 4 doses/day - days 1-6 | ||||
| 2 doses/day - days 7-28 | ||||
| Stout | 22 females | 4 weeks β-ALA or placebo | Continuous graded exercise test on cycle ergometer for VO2max, ventilatory threshold , PWCFT and TTE | β-ALA delays onset of NMF during incremental cycle ergometry (↑ PWCFT, ↑VT, ↑TTE) |
| Ages: | 4 divided doses/day for totals of: | |||
| 28.9 ± 8.1 yrs (β-ALA) | 3.2g/day - days 1-7 | |||
| 25.8 ± 4.0 yrs (placebo) | 6.4g/day - days 8-28 | |||
| Stout | 26 elderly males and females | 90 days supplementation with β-ALA or placebo (microcrystalline cellulose) 3 doses/day of: 2.4 g β-ALA or 2.4 g placebo | Continuous graded exercise test on cycle ergometer for PWCFT with EMG measurements | 28,5% increase in PWCFT after 90 days of β-ALA |
| Sweeney | 19 physically active college-aged males | 5 weeks β-ALA or placebo (rice flour) | 2 sets of 5x5-sec sprints with 45- sec recovery between sprints and 2 min between sets performed on non-motorized treadmill at 15% body weight as resistance | No between group difference for peak or mean horizontal power |
| 4g/day - week 1 | No difference in % fatigue | |||
| 6g/day - weeks 2-5 | No difference in blood lactate pre- and post-testing between groups | |||
| Van Thienen | 17 healthy young males | 8 weeks β-ALA or placebo (maltodextrin) | Simulated road race of 110 minutes intermittent endurance with intensity between 50% and 90% of the maximal lactate steady state (MLSS) in 10 minute stages. Immediately after this, they started a 10 minute time trial at 100% MLSS with voluntary increase of intensity at each minute. | β-ALA enhanced sprint power output at the end of the endurance race compared to placebo |
| 2 g/day - weeks 1-2 | ||||
| 3 g/day - weeks 3-4 | ||||
| 4 g/day - weeks 5-8 | ||||
| Zoeller | 55 males ages 24.5 ± 5.3 yrs | 4 weeks, 4 groups (4 doses/day for first 6 days, then 2 doses/day | Continuous graded exercise test on cycle ergometer | ↑ in 5 cardio-respiratory endurance variables with creatine + β-ALA |
| Placebo - 34g dextrose | Combined supplementation may delay the onset of VT and lactate threshold during incremental cycle exercise | |||
| Creatine - 5.25g creatine monohydrate and 34g dextrose | ||||
| β-ALA - 1.6g β-alanine and 34g dextrose | ||||
| β-ALA plus Creatine - 5.25g creatine monohydrate, 1.6g β-ALA and 34g dextrose |
Summary of recent β-ALA supplementation and exercise training studies.
| Authors | Population | Supplementation Protocol | Exercise Protocol | Muscle Carnosine Concentration Effects | Performance Results |
|---|---|---|---|---|---|
| Hoffman | 33 male strength power athletes | 10 weeks | Resistance training program 4 days/week for 10 weeks | Not measured | ↓ fatigue rate in CA |
| Creatine β-ALA (CA) - 10.5g/day creatine monohydrate and 3.2g/day β-ALA | ↑ ∆ lean body mass and % body fat | ||||
| Creatine (C) - 10.5g/day | No change in power measures | ||||
| Placebo (P) - 10.5g/day dextrose | ↑ training volume in CA | ||||
| Kendrick | 26 healthy males, 19-24 yrs | 800mg x 8/day for 4 weeks of β-ALA or placebo (maltodextrin) | Resistance training 4days/wk for 10 weeks | β-ALA - 23.96 | No difference in whole body strength or isokinetic force |
| Placebo - 29.17 | |||||
| Kendrick | 14 Vietnamese college aged students | 4 weeks β-ALA or placebo (maltodextrin) 800mg x 8/day | Single legged isokinetic training | Carnosine ↑ in both trained and untrained legs with β-ALA | None measured. |
| 3 sessions - weeks 1-2 | Training alone had no effect on carnosine levels | ||||
| 4 sessions - weeks 3-4 | |||||
| 10 × 10 maximal 90° extension and flexion contractions at 180°/sec on Kin-Com | |||||
| Smith | 46 recreationally active young males | 6g/day for 3 weeks, then 3g/day for 2nd 3 weeks of β-ALA or placebo (dextrose) | High intensity interval training | Not measured | Training increased EMGFT, no additive effect with β-ALA |
| Smith | 46 recreationally active young males | 6g/day for 3 weeks, then 3g/day for 2nd 3 weeks of β-ALA or placebo (dextrose) | High intensity interval training | Not measured | ↑ VO2peak and time to reach VO2peak with β-ALA |
| ↑ lean body mass with β-ALA |